These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35936718)

  • 1. Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma.
    Yin XQ; Yin XH; Yu YQ; Xu L; Zhang M
    Front Oncol; 2022; 12():924239. PubMed ID: 35936718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a four-gene panel predicting overall survival for lung adenocarcinoma.
    Li C; Long Q; Zhang D; Li J; Zhang X
    BMC Cancer; 2020 Dec; 20(1):1198. PubMed ID: 33287749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
    Li X; Zhai S; Zhang J; Zhang D; Wang S; Wang L; Yu J
    Front Oncol; 2021; 11():698465. PubMed ID: 34195096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
    Liu J; Wu H; Gao Z; Lou M; Yuan K
    Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma.
    Peng X; Xia Z; Guo Y; Li Y
    Aging (Albany NY); 2023 Jun; 15(11):4889-4905. PubMed ID: 37279937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
    Ma C; Kang W; Yu L; Yang Z; Ding T
    Front Oncol; 2020; 10():590006. PubMed ID: 33363020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
    Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
    Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.
    Liu TT; Li R; Huo C; Li JP; Yao J; Ji XL; Qu YQ
    Front Cell Dev Biol; 2021; 9():682002. PubMed ID: 34409029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma.
    Bian Y; Bi G; Shan G; Liang J; Sui Q; Hu Z; Wang Q; Zhang Y; Fan H
    J Immunol Res; 2023; 2023():4987832. PubMed ID: 36793588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic landscape of ground glass opacities (GGOs) in East Asians.
    Cao P; Hu S; Kong K; Han P; Yue J; Deng Y; Zhao B; Li F
    J Thorac Dis; 2021 Apr; 13(4):2393-2403. PubMed ID: 34012587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.